stockrow
Friday 6 November 2026
Export NORD’s income statement to Excel — free account
Nordicus Partners Corporation
NORD Healthcare Biotechnology
Nordicus Partners Corporation’s revenue for fiscal 2025 (year ended March 2025) was $5,000.00, up 100.0% from fiscal 2024.
- Revenue
- −99.6%
- EPS
- −85.7%
- Free cash flow
- +62.2%
Quarter to June 2026, against a year earlier
3.40
0.33
−8.85%
Follow NORD
Alert me
Nordicus Partners Corporation (NORD) P/E ratio
Nordicus Partners Corporation has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 397× (April 2016) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 349× | — |
| FY2015 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Mar 2025 | 0.0× | — |
| Dec 2024 | 0.0× | — |
| Sep 2024 | 0.0× | — |
| Sep 2018 | 15.4× | — |
| 14 more quarters | Free account |
Against its own ten years
Low 0.0×
High 397×
Ten-year median
0.0×
Current reading's percentile
72
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| CNXU Conexeu Sciences Inc. compare | n/m |
| OKYO OKYO Pharma Limited Sponsored ADR compare | n/m |
| NTRB Nutriband Inc. compare | n/m |
| NORD Nordicus Partners Corporation | n/m |
| MAIA MAIA Biotechnology, Inc. compare | n/m |
| CRBP Corbus Pharmaceuticals Holdings, Inc. compare | n/m |
| COYA Coya Therapeutics, Inc. compare | n/m |
| ACRV Acrivon Therapeutics, Inc. compare | n/m |
| MNOV MediciNova, Inc. compare | n/m |
| Biotechnology industry median | 10.3× |
| Healthcare sector median | 25.2× |
| Market median | 17.9× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)